BB&T Securities LLC lessened its position in shares of ChemoCentryx Inc (NASDAQ:CCXI) by 5.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 130,827 shares of the biopharmaceutical company’s stock after selling 8,000 shares during the quarter. BB&T Securities LLC owned 0.23% of ChemoCentryx worth $887,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. Los Angeles Capital Management & Equity Research Inc. grew its stake in ChemoCentryx by 8.8% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 23,692 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 1,920 shares during the last quarter. A.R.T. Advisors LLC boosted its stake in shares of ChemoCentryx by 9.6% in the second quarter. A.R.T. Advisors LLC now owns 26,176 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 2,300 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of ChemoCentryx by 4.2% in the second quarter. Parametric Portfolio Associates LLC now owns 57,809 shares of the biopharmaceutical company’s stock worth $538,000 after buying an additional 2,319 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of ChemoCentryx in the second quarter worth about $29,000. Finally, Strs Ohio boosted its stake in shares of ChemoCentryx by 6.8% in the second quarter. Strs Ohio now owns 59,600 shares of the biopharmaceutical company’s stock worth $554,000 after buying an additional 3,800 shares during the last quarter. Institutional investors and hedge funds own 60.72% of the company’s stock.
In other ChemoCentryx news, Treasurer Markus J. Cappel sold 330,524 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $32.03, for a total transaction of $10,586,683.72. Following the completion of the transaction, the treasurer now owns 99,764 shares of the company’s stock, valued at $3,195,440.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Susan M. Kanaya sold 311,625 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $31.51, for a total value of $9,819,303.75. Following the transaction, the chief financial officer now directly owns 162,931 shares of the company’s stock, valued at approximately $5,133,955.81. The disclosure for this sale can be found here. Insiders sold a total of 921,315 shares of company stock valued at $29,213,675 in the last ninety days. 12.20% of the stock is currently owned by insiders.
A number of analysts have recently commented on CCXI shares. BidaskClub upgraded ChemoCentryx from a “hold” rating to a “buy” rating in a research note on Monday, October 14th. ValuEngine downgraded ChemoCentryx from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 27th. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $34.00 target price on the stock in a research note on Thursday. Piper Jaffray Companies upped their target price on ChemoCentryx from $17.00 to $54.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 26th. Finally, HC Wainwright upped their target price on ChemoCentryx from $23.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $40.29.
NASDAQ CCXI traded down $1.21 during trading hours on Monday, reaching $29.12. The company’s stock had a trading volume of 1,453,112 shares, compared to its average volume of 627,356. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -38.32 and a beta of 2.07. ChemoCentryx Inc has a 1-year low of $6.16 and a 1-year high of $36.88. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.12 and a quick ratio of 3.12. The company’s 50-day moving average is $10.17 and its two-hundred day moving average is $8.83.
ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. The company had revenue of $10.58 million during the quarter, compared to analysts’ expectations of $7.83 million. ChemoCentryx had a negative return on equity of 88.76% and a negative net margin of 143.30%. Equities analysts forecast that ChemoCentryx Inc will post -0.98 EPS for the current fiscal year.
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for ChemoCentryx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ChemoCentryx and related companies with MarketBeat.com’s FREE daily email newsletter.